118 related articles for article (PubMed ID: 25290986)
1. Epigenetic pathways and glioblastoma treatment: insights from signaling cascades.
Allen BK; Stathias V; Maloof ME; Vidovic D; Winterbottom EF; Capobianco AJ; Clarke J; Schurer S; Robbins DJ; Ayad NG
J Cell Biochem; 2015 Mar; 116(3):351-63. PubMed ID: 25290986
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Epigenetic Modifications on Adaptive Resistance Evolution in Glioblastoma.
Wu Q; Berglund AE; Etame AB
Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361090
[TBL] [Abstract][Full Text] [Related]
3. The Role of Non-Coding RNAs in Epigenetic Dysregulation in Glioblastoma Development.
Isachesku E; Braicu C; Pirlog R; Kocijancic A; Busuioc C; Pruteanu LL; Pandey DP; Berindan-Neagoe I
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003512
[TBL] [Abstract][Full Text] [Related]
4. Comparative epigenetic analysis of tumour initiating cells and syngeneic EPSC-derived neural stem cells in glioblastoma.
Vinel C; Rosser G; Guglielmi L; Constantinou M; Pomella N; Zhang X; Boot JR; Jones TA; Millner TO; Dumas AA; Rakyan V; Rees J; Thompson JL; Vuononvirta J; Nadkarni S; El Assan T; Aley N; Lin YY; Liu P; Nelander S; Sheer D; Merry CLR; Marelli-Berg F; Brandner S; Marino S
Nat Commun; 2021 Oct; 12(1):6130. PubMed ID: 34675201
[TBL] [Abstract][Full Text] [Related]
5. The good, the bad and the ugly: epigenetic mechanisms in glioblastoma.
Carén H; Pollard SM; Beck S
Mol Aspects Med; 2013; 34(4):849-62. PubMed ID: 22771539
[TBL] [Abstract][Full Text] [Related]
6. Systems Medicine for Precise Targeting of Glioblastoma.
Zeng J; Zeng XX
Mol Biotechnol; 2023 Oct; 65(10):1565-1584. PubMed ID: 36859639
[TBL] [Abstract][Full Text] [Related]
7. From signalling pathways to targeted therapies: unravelling glioblastoma's secrets and harnessing two decades of progress.
Dewdney B; Jenkins MR; Best SA; Freytag S; Prasad K; Holst J; Endersby R; Johns TG
Signal Transduct Target Ther; 2023 Oct; 8(1):400. PubMed ID: 37857607
[TBL] [Abstract][Full Text] [Related]
8. Single-cell lineage analysis reveals genetic and epigenetic interplay in glioblastoma drug resistance.
Eyler CE; Matsunaga H; Hovestadt V; Vantine SJ; van Galen P; Bernstein BE
Genome Biol; 2020 Jul; 21(1):174. PubMed ID: 32669109
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic modifiers either individually or in specific combinations impair viability of patient-derived glioblastoma cell line while exhibiting moderate effect on normal stem cells growth.
Alexanian A; Stoellinger H; De Araujo Farias V; Quinones-Hinojosa A
Res Sq; 2023 Mar; ():. PubMed ID: 36993520
[TBL] [Abstract][Full Text] [Related]
10. 'Slicing' glioblastoma drivers with the Swiss cheese model.
Teran Pumar OY; Lathia JD; Watson DC; Bayik D
Trends Cancer; 2024 Jan; 10(1):15-27. PubMed ID: 37625928
[TBL] [Abstract][Full Text] [Related]
11. Glioblastoma: Not Just Another Cancer.
Fine HA
Cancer Discov; 2024 Apr; 14(4):648-652. PubMed ID: 38571415
[TBL] [Abstract][Full Text] [Related]
12. Seeing the GBM diversity spectrum.
Hubert CG; Lathia JD
Nat Cancer; 2021 Feb; 2(2):135-137. PubMed ID: 35122081
[No Abstract] [Full Text] [Related]
13. Emerging treatment strategies for glioblastoma multiforme.
Carlsson SK; Brothers SP; Wahlestedt C
EMBO Mol Med; 2014 Nov; 6(11):1359-70. PubMed ID: 25312641
[TBL] [Abstract][Full Text] [Related]
14. DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors.
Mazor T; Pankov A; Johnson BE; Hong C; Hamilton EG; Bell RJA; Smirnov IV; Reis GF; Phillips JJ; Barnes MJ; Idbaih A; Alentorn A; Kloezeman JJ; Lamfers MLM; Bollen AW; Taylor BS; Molinaro AM; Olshen AB; Chang SM; Song JS; Costello JF
Cancer Cell; 2015 Sep; 28(3):307-317. PubMed ID: 26373278
[TBL] [Abstract][Full Text] [Related]
15. Molecular and Genomic Alterations in Glioblastoma Multiforme.
Crespo I; Vital AL; Gonzalez-Tablas M; Patino Mdel C; Otero A; Lopes MC; de Oliveira C; Domingues P; Orfao A; Tabernero MD
Am J Pathol; 2015 Jul; 185(7):1820-33. PubMed ID: 25976245
[TBL] [Abstract][Full Text] [Related]
16. New strategies in glioblastoma: exploiting the new biology.
Fine HA
Clin Cancer Res; 2015 May; 21(9):1984-8. PubMed ID: 25670220
[TBL] [Abstract][Full Text] [Related]
17. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
18. Blocking of the interaction between Wnt proteins and their co-receptors contributes to the anti-tumor effects of adenovirus-mediated DKK3 in glioblastoma.
Hara K; Kageji T; Mizobuchi Y; Kitazato KT; Okazaki T; Fujihara T; Nakajima K; Mure H; Kuwayama K; Hara T; Nagahiro S
Cancer Lett; 2015 Jan; 356(2 Pt B):496-505. PubMed ID: 25301448
[TBL] [Abstract][Full Text] [Related]
19. The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.
Poulsen HS; Urup T; Michaelsen SR; Staberg M; Villingshøj M; Lassen U
Cancer Manag Res; 2014; 6():373-87. PubMed ID: 25298738
[TBL] [Abstract][Full Text] [Related]
20. Strong therapeutic potential of γ-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells.
Tanaka S; Nakada M; Yamada D; Nakano I; Todo T; Ino Y; Hoshii T; Tadokoro Y; Ohta K; Ali MA; Hayashi Y; Hamada J; Hirao A
J Neurooncol; 2015 Jan; 121(2):239-50. PubMed ID: 25293440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
